BYSI - BeyondSpring Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
BYSI price evolution
BYSI
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $41.63 | |||
| Short term investments | $17.57 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $25.79 | $38.52 | $55.73 | $75.12 |
| Long term investments | ||||
| Property, plant & equipment | $6.75 | $7.35 | $7.92 | $3.41 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $32.88 | $46.22 | $63.77 | $81.65 |
| Current liabilities | ||||
| Accounts payable | $1.5 | $1.08 | $1.16 | $1.66 |
| Deferred revenue | ||||
| Short long term debt | $1.57 | |||
| Total current liabilities | $6.82 | $7.35 | $11.11 | $15.15 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $50.97 | $52.2 | $55.66 | $55.27 |
| Shareholders' equity | ||||
| Retained earnings | -$388 | -$375.28 | -$360.49 | -$342 |
| Other shareholder equity | $1.22 | $0.44 | $0.12 | -$0.52 |
| Total shareholder equity | $26.68 | |||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $41.63 | $109.54 | $35.93 | |
| Short term investments | $17.57 | |||
| Net receivables | $3.5 | $4.5 | ||
| Inventory | ||||
| Total current assets | $38.52 | $75.12 | $113.4 | $40.86 |
| Long term investments | ||||
| Property, plant & equipment | $7.35 | $3.41 | $2.36 | $2.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.64 | $3.69 | ||
| Total investments | ||||
| Total assets | $46.22 | $81.65 | $117.04 | $44.55 |
| Current liabilities | ||||
| Accounts payable | $1.08 | $1.66 | $2.22 | $2.54 |
| Deferred revenue | $1.35 | |||
| Short long term debt | $1.57 | |||
| Total current liabilities | $7.35 | $15.15 | $13.77 | $10.05 |
| Long term debt | $2.17 | $1.44 | ||
| Total noncurrent liabilities | $16.65 | $3.37 | ||
| Total debt | ||||
| Total liabilities | $52.2 | $55.27 | $25.22 | $13.42 |
| Shareholders' equity | ||||
| Retained earnings | -$375.28 | -$342 | -$277.82 | -$216.84 |
| Other shareholder equity | $0.44 | -$0.52 | -$0.3 | $0.14 |
| Total shareholder equity | $26.68 | $88.34 | $30.28 | |
| (in millions $) | 30 Jul 2023 | 31 Jan 2023 | 30 Jul 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.88 | $1.35 | $0.68 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $14.36 | $38.59 | $21.48 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.01 | $0.16 | $0.29 | |
| Interest expense | $0.08 | -$0.25 | -$0.33 | |
| Net income | ||||
| Net income | -$12.72 | -$33.28 | -$18.49 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.35 | $0.18 | ||
| Cost of revenue | ||||
| Gross Profit | $0.18 | |||
| Operating activities | ||||
| Research & development | $41.79 | $31.34 | ||
| Selling, general & administrative | $22.6 | $8.96 | ||
| Total operating expenses | $38.59 | $64.39 | $40.31 | |
| Operating income | -$64.21 | -$40.31 | ||
| Income from continuing operations | ||||
| EBIT | -$64.21 | -$40.31 | ||
| Income tax expense | $0.16 | |||
| Interest expense | -$0.25 | -$0.09 | -$0.21 | |
| Net income | ||||
| Net income | -$33.28 | -$60.97 | -$38.09 | |
| Income (for common shares) | -$60.97 | -$38.09 | ||
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 29 Sep 2021 | 30 Jul 2021 |
|---|---|---|---|---|
| Net income | -$9.51 | -$18.37 | -$37.34 | |
| Operating activities | ||||
| Depreciation | $0.01 | $0.02 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$16.92 | $2.83 | -$33.15 | |
| Investing activities | ||||
| Capital expenditures | -$2.81 | -$0.02 | ||
| Investments | -$1.92 | $9.36 | ||
| Total cash flows from investing | $18.25 | -$4.73 | $9.34 | -$25.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $3.43 | $0 | ||
| Effect of exchange rate | -$0.76 | -$0.16 | -$0.04 | -$0.06 |
| Change in cash and equivalents | -$7.23 | -$21.81 | $12.13 | -$58.23 |
| (in millions $) | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Net income | -$64.18 | -$60.97 | -$38.09 | |
| Operating activities | ||||
| Depreciation | $0.06 | $0.08 | $0.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$47.24 | -$43.74 | -$48.16 | |
| Investing activities | ||||
| Capital expenditures | -$2.84 | -$0.05 | -$0 | |
| Investments | -$17.57 | |||
| Total cash flows from investing | $18.25 | -$20.41 | -$0.05 | -$0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $0.61 | $1.52 | ||
| Total cash flows from financing | $3.43 | $0 | $117.83 | $80.17 |
| Effect of exchange rate | -$0.76 | -$0.26 | -$0.43 | $0.04 |
| Change in cash and equivalents | -$7.23 | -$67.91 | $73.6 | $32.04 |
News
Fundamentals
| Market cap | $94.81M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 39.02M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 159.64% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.78 |
| Quick ratio | N/A |